La chaîne d'options affiche les données clés des options sur actions de Ayr Wellness à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Ayr Wellness..

Ayr Wellness (OTC:AYRWF) Stock, Chaîne d'Options

Ayr Wellness Inc is a vertically integrated cannabis multi-state operator in the United States of America. Through its subsidiaries in various U.S. states, it is involved in the cultivation, manufacturing, and retail of cannabis products and branded cannabis packaged goods. It operates in one operating segment, cannabis sales. It has a single operating and reportable segment, the production and sale of cannabis.

Ordinary Shares (Sub, Restricted, Ltd Voting)

Ayr Wellness Inc

News

NUWE

Nuwellis Finalizes Agreement With KDI Precision Manufacturing; Manufacturing Operations Will Transition To KDI's Facility

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>, TASE: GILT))), a worldwide leader in satellite networking technology, solutions and services, announced today the successful completion of a series of test flights featuring its ESR-2030Ku electronically steered antenna (ESA). Conducted in collaboration with Gogo, which will be the exclusive distributor of the antenna for the business aviation and defense markets, the tests demonstrated outstanding performance of the ESA on the OneWeb Low Earth Orbit (LEO) network.
The ESR-2030Ku—designed for mobility and engineered for efficiency—delivered full-duplex connectivity with throughput of 195 Mbps downlink and 32 Mbps uplink. The terminal remained stable and reliable throughout the tests, even in demanding performance scenarios.

GILT

Gilat Satellite Networks Completes Series Of Test Flights Featuring ESR-2030Ku Electronically Steered Antenna

Federal health officials have linked a listeria outbreak that hospitalized 10 people to a California-based food producer, prompting a voluntary recall of ready-to-eat products across four western states.
What Happened: The U.S. Food and Drug Administration announced Saturday that San Fernando-based Fresh &amp; Ready Foods LLC has been identified as the source of contamination that sickened people in California and Nevada, <a href="https://apnews.com/article/listeria-outbreak-food-sick-c11ddb49f357f227797fe42c468115f5">reported</a> the Associated Press. 
The investigation initially began last year but was reopened in April when FDA investigators found listeria in samples collected from Fresh &amp; Ready Foods that matched the strain from the outbreak. 
The contaminated products were distributed to retailers and food service points of sale, including hospitals, hotels, convenience stores, airports and by airlines in Arizona, California, Nevada and Washington, according to the FDA. 
Fresh &amp; Ready Foods has voluntarily recalled several products with &#8220;use by&#8221; dates from April 22 to May 19 under multiple brand names: Fresh &amp; Ready Foods, City Point Market Fresh Food to Go and Fresh Take Crave Away.
See Also: <a href="https://www.benzinga.com/markets/25/05/45342977/trumps-tariffs-reportedly-push-walmart-and-target-toy-suppliers-to-the-brink-of-closure-if-nothing-changes-well-be-crippled">Trump&#8217;s Tariffs Reportedly Push Walmart And Target Toy Suppliers To The Brink Of Closure: &#8216;If Nothing Changes, We&#8217;ll Be Crippled&#8217;</a>
Why It Matters: Fresh &amp; Ready Foods said in a news release that it took immediate corrective actions, including removing equipment to address the issue, AP report noted. 
The Centers for Disease Control and Prevention noted that test samples from sick patients were collected between December 2023 and September 2024, with six of the 10 affected individuals having been hospitalized before contracting listeria.
This outbreak follows a similar recall by Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) which voluntarily recalled 12 types of ReadyMeals and deli items supplied by Fresh Creative Foods due to <a href="https://www.benzinga.com/markets/equities/24/10/41310010/listeria-scare-prompts-albertsons-to-recall-certain-ready-to-eat-meals-in-multiple-states?utm_source=chatgpt.com">potential contamination with Listeria monocytogenes</a>. 
That recall was <a href="https://www.benzinga.com/markets/equities/24/10/41310010/listeria-scare-prompts-albertsons-to-recall-certain-ready-to-eat-meals-in-multiple-states?utm_source=chatgpt.com">triggered after routine tests</a> by the U.S. Department of Agriculture&#8217;s Food Safety and Inspection Service (FSIS) detected contamination in a ready-to-eat chicken ingredient from BrucePac in Durant, Oklahoma. 
The recalled items were sold across several major retail chains including Albertsons, Safeway, Jewel-Osco, Vons, and stores across several states, including California, Texas, Illinois, and Washington.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45342962/bill-gates-slams-trumps-tariffs-we-told-china-to-make-their-own-chips-and-theyre-making-great-progress-warns-its-a-bad-time-to-inte">Bill Gates Slams Trump&#8217;s Tariffs: We Told China To &#8216;Make Their Own Chips&#8217; —And &#8216;They&#8217;re Making Great Progress,&#8217; Warns It&#8217;s A &#8216;Bad Time To Interject So Much Uncertainty&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Regulations

Health Care

Listeria Outbreak Linked To California's Fresh & Ready Foods Prompts Recall Across 4 States — 10 Hospitalized As FDA, CDC Investigate Contamination

HC Wainwright &amp; Co. analyst Yi Chen maintains Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) with a Buy and raises the price target from $57 to $60.

Price Target

Analyst Ratings

HROW

HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $60

Raises $510 Million PIPE and $200 Million in Convertible Notes Marking Largest Capital Raise to Launch a Bitcoin Treasury and the Largest PIPE for Any Public Crypto-Related Transaction
David Bailey, Founder of BTC Inc and UTXO, to Lead Combined Company as CEO
Transaction Reflects Shared Belief in Bitcoin's Long-Term Value and Positions Combined Company as a Leading Public Market Bitcoin Treasury
KindlyMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>, "KindlyMD"))), a leading provider of integrated healthcare services, today announced that it has entered into a definitive merger agreement with Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding company, to start a Bitcoin treasury strategy.
Nakamoto is a new holding company founded by David Bailey. In partnership with BTC Inc, Nakamoto seeks to build the first global network of Bitcoin treasury companies. This is the first step in Nakamoto's vision for an ecosystem of Bitcoin-native companies, including media, advisory, and financial services, that exist to accelerate Bitcoin adoption and utility.
The combined company will aim both to accumulate Bitcoin and grow the Bitcoin owned on a per share basis, or Bitcoin Yield, through a variety of equity, debt and other offerings. This merger gives the public market exposure to Bitcoin within a compliant, transparent structure backed by a uniquely experienced Bitcoin management team, including a partnership with one of the world's most influential Bitcoin marketing platforms.
The PIPE financing attracted participation from over 200 investors across six continents, including global investment firms and leaders across the Bitcoin ecosystem. Institutional investors include Actai Ventures, Arrington Capital, BSQ Capital Partners, Kingsway, Off the Chain Capital, ParaFi, RK Capital, Van Eck, and Yorkville Advisors, alongside individuals including Adam Back, Balaji Srinivasan, Danny Yang, Eric Semler (CEO of Semler Scientific), Jihan Wu, Ricardo Salinas, and Simon Gerovich (CEO of Metaplanet). YA II PN, Ltd., an investment fund managed by Yorkville Advisors, was the sole convertible note purchaser.
Upon the close of the transaction, the combined company will be led by Founder and CEO David Bailey, a leader within the Bitcoin ecosystem and an influential advocate for hyperbitcoinization, the inflection point at which Bitcoin becomes the default value system of the world. As Co-Founder and CEO of BTC Inc – the company behind Bitcoin Magazine and the global annual Bitcoin Conferences – and General Partner of Bitcoin-focused investment firm UTXO Management, Mr. Bailey has built industry-leading platforms at the heart of the Bitcoin ecosystem. Mr. Bailey will be supported by a seasoned management team with decades of experience operating in the Bitcoin space.
Transaction Summary
Shares of KindlyMD will continue to trade on Nasdaq under the symbol "KDLY." The combined company expects to be renamed and trade under a new ticker symbol.
The Board of Directors of Nakamoto and KindlyMD have unanimously approved the transaction. The transaction will require the approval of the shareholders of KindlyMD and is subject to customary closing conditions.
The transaction includes $510 million in gross proceeds from a fully committed private placement in public equity ("PIPE Financing") priced at $1.12 per share and consisting of common stock and pre-funded warrants in KindlyMD and $200 million in gross proceeds from the sale of senior secured convertible notes of KindlyMD that mature in 2028 (the "Debt Financing"). The PIPE and Debt Financings are expected to close concurrently with the merger.
As part of the merger, the combined company will assume the rights and obligations of Nakamoto under its marketing services agreement with BTC Inc, whereby BTC Inc provides certain marketing services to Nakamoto and, following the closing of the merger, will provide such services to the combined company in connection with its Bitcoin treasury and related operations.

KDLY

KindlyMD Enters InTo Definitive Merger Agreement With Nakamoto Holdings To Establish Bitcoin Treasury; Raises $510M PIPE and $200M In Convertible Notes

Dentalcorp Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DNTL#TSX">DNTL</a>) sees Q2 sales of $435.800 million-$439.800 million vs $440.66 million analyst estimate.

Guidance

TSX:DNTL

Dentalcorp Holdings Sees Q2 Sales $435.800M-$439.800M vs $440.66M Est

D. Boral Capital analyst Jesse Sobelson maintains United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) with a Buy and maintains $5 price target.

UAMY

D. Boral Capital Maintains Buy on United States Antimony, Maintains $5 Price Target

Biotech

General

IVVD

Invivyd Announces Initiates Discovery Program For A Measles Monoclonal Antibody Treatment

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and maintains $45 price target.

Reiteration

CMPS

HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $45 Price Target

Earnings

Earnings Misses

ISPR

Ispire Technology Q3 EPS $(0.19) Misses $(0.12) Estimate, Sales $26.19M Miss $31.80M Estimate

In Q1 2025, Beamr expanded sales pipelines amid growing traction from large-scale prospects, engaged in major industry events, and continued innovation in cloud and product offerings

Beamr CEO Issues Q1 Shareholder Letter Highlighting 55% Revenue Growth, Expanding Sales Pipeline, And Rising Demand Across Video Verticals

Dorel Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DII#TSX">DII</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.36) by 100 percent. This is a 38.46 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $320.46 million which missed the analyst consensus estimate of $347.80 million by 7.86 percent. This is a 8.72 percent decrease over sales of $351.07 million the same period last year.

TSX:DII

TSX:DII.A

Dorel Industries Q1 Adj. EPS $(0.72) Misses $(0.36) Estimate, Sales $320.46M Miss $347.80M Estimate

NRG Energy Inc. To Acquire A Portfolio Of Natural Gas Generation Facilities And A Commercial & Industrial Virtual Power Plant Platform From LS Power In Cash And Stock Transaction Valued At ~$12B Enterprise Value; Says Immediately Accretive To Adj. EPS, NRG Increases 5-Year Adj. EPS CAGR From +10% To +14%, Before Upside Opportunities

Dentalcorp Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DNTL#TSX">DNTL</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.14 by 28.57 percent. This is a 23.08 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $409.40 million which beat the analyst consensus estimate of $404.60 million by 1.19 percent. This is a 9.94 percent increase over sales of $372.40 million the same period last year.

Earnings Beats

Dentalcorp Holdings Q1 Adj. EPS $0.10 Misses $0.14 Estimate, Sales $409.40M Beat $404.60M Estimate

Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) .

Superior Industries Intl  is withdrawing its 2025 fiscal year outlook due to the uncertainties related to the current macroeconomic environment as well as the lost volume from certain customers

Macerich Q1 FFO $0.33 Beats $0.31 Estimate, Sales $249.22M Beat $220.01M Estimate

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) sees Q2 sales of $18.000 million-$20.000 million vs $19.20 million analyst estimate.

HBIO

Harvard Bioscience Sees Q2 Sales $18.000M-$20.000M vs $19.20M Est

Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) affirms FY2025 sales outlook from $84.00 million-$88.00 million to $84.00 million-$88.00 million vs $75.30 million estimate.

Wag Group Affirms FY2025 Sales Guidance of $84.00M-$88.00M Vs $75.30M Est.

Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $5.39 million which missed the analyst consensus estimate of $6.69 million by 19.45 percent. This is a 16.67 percent decrease over sales of $6.47 million the same period last year.

TNGX

Tango Therapeutics Q1 EPS $(0.36) Misses $(0.35) Estimate, Sales $5.39M Miss $6.69M Estimate

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) sees Q2 sales of $292.000 million-$294.000 million vs $275.78 million analyst estimate.

Comments

Ayr Wellness

Ayr Wellness (AYRWF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL